Trial Profile

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Necitumumab (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Paclitaxel (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms QUILT-3.090
Sponsors ImmunityBio; NantKwest

05 Aug 2024 Status changed from active, no longer recruiting to discontinued, study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
10 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2021.
10 Aug 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com